Policy & Medicine November 6, 2024
With Donald Trump now confirmed as the President-elect, the life sciences industry is bracing for significant policy shifts that could impact everything from drug pricing to regulatory practices. Trump’s previous term may offer clues about his likely approach to healthcare, Food and Drug Administration (FDA) regulations, and trade policies, all of which hold meaningful implications for pharmaceutical companies, biotech firms, and healthcare providers. Below, we explore key areas of potential change and how the life sciences sector might adapt to a new Trump administration.
FDA and Accelerated Approvals
During his prior administration, Trump championed a faster and more flexible FDA approval process, prioritizing efficiency in getting new therapies to market. His leadership saw the FDA streamline approvals, especially for innovative...
Today's Sponsors
Today's Sponsor